extract: 2025-11-06-trump-novo-lilly-glp1-price-deals-medicare (#1143)

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -53,6 +53,12 @@ The BALANCE Model directly addresses the chronic use inflation problem by requir
 
 At net prices with 48% rebates, semaglutide achieves $32,219/QALY ICER, making it highly cost-effective. The Trump Medicare deal at $245/month (82% discount) would push ICER below $30K/QALY. The inflationary claim may need scope qualification: GLP-1s are inflationary at list prices but potentially cost-saving at negotiated net prices, and the price trajectory is declining faster than the 2035 projection anticipated.
 
+
+### Additional Evidence (challenge)
+*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16*
+
+The Trump Administration's Medicare GLP-1 deal establishes $245/month pricing (82% below list) with narrow eligibility criteria requiring comorbidities (BMI ≥27 with prediabetes/CVD or BMI >30 with heart failure/hypertension/CKD). This targets ~10% of Medicare beneficiaries—specifically the high-risk population where downstream savings (24% kidney disease progression reduction, cardiovascular protection) offset drug costs under capitation. The narrow eligibility is the mechanism that changes the cost-effectiveness calculus: inflationary impact depends on population breadth, not just drug price.
+
 ---
 
 Relevant Notes:

domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md

@@ -47,6 +47,12 @@ This data comes from commercially insured populations (younger, fewer comorbidit
 
 No data yet on whether payment model affects persistence—does being in an MA plan with care coordination improve adherence vs. fee-for-service? This is directly relevant to value-based care design.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16*
+
+The $50/month out-of-pocket maximum for Medicare beneficiaries (starting April 2026 for tirzepatide) removes most financial barriers to persistence for the eligible population. Lower-income patients show higher discontinuation rates, suggesting affordability drives persistence. The OOP cap may improve persistence rates specifically in Medicare, though this remains untested.
+
 ---
 
 Relevant Notes:

domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md

@@ -37,6 +37,12 @@ At $245/month list price, even modest copays ($50-100/month) create a sustained
 
 The source does not provide granular income-stratified discontinuation rates, so the magnitude of the effect is unclear. It's possible income is a proxy for other factors (health literacy, access to care coordination, baseline health status) rather than affordability per se.
 
+
+### Additional Evidence (confirm)
+*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16*
+
+The Trump Administration deal establishes a $50/month out-of-pocket maximum for Medicare beneficiaries, explicitly targeting affordability as a persistence barrier. The $245/month Medicare price (down from ~$1,350) combined with the OOP cap is designed to address the affordability-driven discontinuation pattern observed in lower-income populations.
+
 ---
 
 Relevant Notes:

inbox/archive/.extraction-debug/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.json

@@ -0,0 +1,32 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "narrow-eligibility-targeting-high-risk-patients-makes-glp-1-coverage-cost-effective-under-capitation-despite-high-drug-costs.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    },
+    {
+      "filename": "manufacturer-price-concessions-in-exchange-for-coverage-expansion-is-a-novel-policy-mechanism-bypassing-traditional-cms-rulemaking.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 2,
+    "kept": 0,
+    "fixed": 2,
+    "rejected": 2,
+    "fixes_applied": [
+      "narrow-eligibility-targeting-high-risk-patients-makes-glp-1-coverage-cost-effective-under-capitation-despite-high-drug-costs.md:set_created:2026-03-16",
+      "manufacturer-price-concessions-in-exchange-for-coverage-expansion-is-a-novel-policy-mechanism-bypassing-traditional-cms-rulemaking.md:set_created:2026-03-16"
+    ],
+    "rejections": [
+      "narrow-eligibility-targeting-high-risk-patients-makes-glp-1-coverage-cost-effective-under-capitation-despite-high-drug-costs.md:missing_attribution_extractor",
+      "manufacturer-price-concessions-in-exchange-for-coverage-expansion-is-a-novel-policy-mechanism-bypassing-traditional-cms-rulemaking.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-16"
+}

inbox/archive/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.md

@@ -7,9 +7,13 @@ date: 2025-11-06
 domain: health
 secondary_domains: [internet-finance]
 format: news
-status: unprocessed
+status: enrichment
 priority: high
 tags: [glp-1, drug-pricing, medicare, policy, trump-administration, market-structure]
+processed_by: vida
+processed_date: 2026-03-16
+enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -45,3 +49,12 @@ On November 6, 2025, President Trump announced agreements with Eli Lilly and Nov
 PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
 WHY ARCHIVED: The price reduction + coverage expansion + narrow eligibility criteria fundamentally change the economics analyzed in the existing claim — the "inflationary through 2035" conclusion assumed higher prices and broader population
 EXTRACTION HINT: Focus on how narrow eligibility (comorbid patients only) changes the cost-effectiveness calculus vs. broad population coverage
+
+
+## Key Facts
+- Medicare GLP-1 payment demonstration begins July 2026
+- BALANCE Model in Medicaid begins May 2026
+- BALANCE Model in Medicare Part D begins January 2027
+- Oral Wegovy launches January 2026 at $149-$299/month
+- Medicare beneficiary out-of-pocket maximum for tirzepatide is $50/month starting April 2026
+- Approximately 10% of Medicare beneficiaries expected to be eligible under comorbidity criteria